-
Study aim
-
The effect of spirulina (Arthrospira plantensis) supplementation on nutritional status, hormonal status, cardiometabolic indices and clinical symptoms in women with polycystic ovary syndrome
-
Design
-
A clinical trial with a control group, parallel groups, double-blind, randomized using RASS software, on 46 patients
-
Settings and conduct
-
Participants meeting the criteria will be assigned to intervention or placebo groups with the same protocol. Anthropometric assessments, relevant questionnaires, and a 5-cc fasting blood sample will be obtained at baseline and study completion for biochemical analysis.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria included willingness to participate in the study; women diagnosed with polycystic ovary syndrome (PCOS) by a physician based on the Rotterdam criteria; age between 20 to 45 years; BMI between 25 and 35. Exclusion criteria consisted of a history of liver, kidney, cardiovascular diseases , diabetes , Cushing’s syndrome, or hyperprolactinemia; pregnancy or lactation; allergy to algae or seafood products; use of weight loss medications, oral contraceptive pills for contraception, regular physical activity, adherence to a specific diet, or use of any dietary supplements (including nutritional or herbal supplements) within the past three months; and smoking, alcohol consumption, or hookah use.
-
Intervention groups
-
The intervention group will consume three capsules of Spirulina algae daily, with a dose of 500 mg, while the placebo group will receive three capsules of maltodextrin identical in appearance and packaging to the supplement. Both groups will take the capsules with their meals to enhance absorption, for a duration of 12 weeks.
-
Main outcome variables
-
The nutritional status, hormonal status , cardiometabolic indices , and clinical symptoms